These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 33237382)

  • 21. Physiologically based pharmacokinetic modeling to assess the drug-drug interactions of anaprazole with clarithromycin and amoxicillin in patients undergoing eradication therapy of H. pylori infection.
    Liang N; Zhou S; Li T; Zhang Z; Zhao T; Li R; Li M; Shao F; Wang G; Sun J
    Eur J Pharm Sci; 2023 Oct; 189():106534. PubMed ID: 37480962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiologically Based Pharmacokinetic Modeling of Palbociclib.
    Yu Y; Loi CM; Hoffman J; Wang D
    J Clin Pharmacol; 2017 Feb; 57(2):173-184. PubMed ID: 27402157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats.
    Scotcher D; Melillo N; Tadimalla S; Darwich AS; Ziemian S; Ogungbenro K; Schütz G; Sourbron S; Galetin A
    Mol Pharm; 2021 Aug; 18(8):2997-3009. PubMed ID: 34283621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).
    Duan P; Zhao P; Zhang L
    Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):689-705. PubMed ID: 27858342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.
    Hanke N; Frechen S; Moj D; Britz H; Eissing T; Wendl T; Lehr T
    CPT Pharmacometrics Syst Pharmacol; 2018 Oct; 7(10):647-659. PubMed ID: 30091221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Physiologically Based Pharmacokinetic Model for Optimally Profiling Lamotrigine Disposition and Drug-Drug Interactions.
    Conner TM; Reed RC; Zhang T
    Eur J Drug Metab Pharmacokinet; 2019 Jun; 44(3):389-408. PubMed ID: 30460522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.
    Schlender JF; Meyer M; Thelen K; Krauss M; Willmann S; Eissing T; Jaehde U
    Clin Pharmacokinet; 2016 Dec; 55(12):1573-1589. PubMed ID: 27351180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug-drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model.
    Perrier J; Gualano V; Helmer E; Namour F; Lukacova V; Taneja A
    Clin Transl Sci; 2023 Nov; 16(11):2222-2235. PubMed ID: 37667518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine.
    Wiebe ST; Giessmann T; Hohl K; Schmidt-Gerets S; Hauel E; Jambrecina A; Bader K; Ishiguro N; Taub ME; Sharma A; Ebner T; Mikus G; Fromm MF; Müller F; Stopfer P
    Clin Pharmacokinet; 2020 Dec; 59(12):1627-1639. PubMed ID: 32504272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation Method.
    Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
    AAPS J; 2020 Oct; 22(6):129. PubMed ID: 33033962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transporters.
    Ahmad A; Ogungbenro K; Kunze A; Jacobs F; Snoeys J; Rostami-Hodjegan A; Galetin A
    CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):467-477. PubMed ID: 33704919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.
    Neuhoff S; Yeo KR; Barter Z; Jamei M; Turner DB; Rostami-Hodjegan A
    J Pharm Sci; 2013 Sep; 102(9):3161-73. PubMed ID: 23686764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling.
    Posada MM; Bacon JA; Schneck KB; Tirona RG; Kim RB; Higgins JW; Pak YA; Hall SD; Hillgren KM
    Drug Metab Dispos; 2015 Mar; 43(3):325-34. PubMed ID: 25504564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N-desbutyldronedarone: Application to prospective simulation of complex drug-drug interaction with rivaroxaban.
    Leow JWH; Ang XJ; Chan ECY
    Br J Clin Pharmacol; 2023 Jun; 89(6):1873-1890. PubMed ID: 36683488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates.
    Chen Y; Samineni D; Mukadam S; Wong H; Shen BQ; Lu D; Girish S; Hop C; Jin JY; Li C
    Clin Pharmacokinet; 2015 Jan; 54(1):81-93. PubMed ID: 25223698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans.
    Min JS; Kim D; Park JB; Heo H; Bae SH; Seo JH; Oh E; Bae SK
    Drug Des Devel Ther; 2016; 10():2959-2972. PubMed ID: 27695293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone.
    Chen Y; Mao J; Hop CE
    Drug Metab Dispos; 2015 Feb; 43(2):182-9. PubMed ID: 25324279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
    Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
    Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.
    Chiney MS; Ng J; Gibbs JP; Shebley M
    Clin Pharmacokinet; 2020 May; 59(5):617-627. PubMed ID: 31713224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach.
    Otsuka K; Wagner C; Selen A; Dressman J
    J Pharm Pharmacol; 2015 May; 67(5):651-65. PubMed ID: 25644429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.